Johnson & Johnson announced the U.S. FDA approval of a supplemental New Drug Application for Spravato CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $159 from $160 at Barclays
- Johnson & Johnson (JNJ) Q4 Pre-Earnings: Here’s What to Expect
- Nanobiotix doses first patient in CONVERGE study
- Options Volatility and Implied Earnings Moves This Week, January 21 – January 24, 2025
- JNJ Earnings Report this Week: Is It a Buy, Ahead of Earnings?